| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e21097354ff784c1df693905428eed8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0aaa248dc70181d26be9fcbc6e8fbbdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b74695f4c6259a8598b722c1ef6eefa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7da5c8e8c3e8261efe7e698c7198681b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2021-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b9196dfadb71ae1798024d83dd01716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c600ac2d053bd59b9de5d95642976f99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1047f0d401deca8a90990f811ac30a69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_294baf36ccc53bf556a3056e38ee26ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4594cce5260e55e5d5114bd2ab871860
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0b71973d57252a8e8f28067be74860f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efed20c97a8f798a010504f7bdcc8e39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29eae81c4880a24819dce8e7f0a65a4a |
| publicationDate |
2022-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4029500-A1 |
| titleOfInvention |
Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the nrf2-beta-trcp interaction for use in the treatment of nrf2-related diseases |
| abstract |
The present invention relates to NRF2-βTrCP interaction inhibitors for use in the treatment of NRF2-related diseases. |
| priorityDate |
2021-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |